Pharma Two B Appoints Sheila Oren, M.D., M.B.A., as Chief Executive Officer
Dr. Oren Has 25 Years’ Experience in Global Drug Development Leadership; Proven Track Record in PD REHOVOT, Israel, Jan. 05,
Press Release
Pharma Two B Appoints David S. Tierney, M.D. as the Company’s Chief Executive Officer
Rehovot, Israel – February 18, 2020 – Pharma Two B Ltd., a privately held company developing innovative therapeutics based on
First Patients Dosed in Phase III Multi-center, Multinational Study to Determine the Efficacy, Safety and Tolerability of P2B001 in Patients with Early Stage Parkinson’s Disease
Based on positive data from a Phase IIb pivotal study suggesting that P2B001 may offer effective therapy with minimal side
Pharma Two B Ltd. Closes $30 Million Financing Round
REHOVOTH, Israel, February 27, 2017 — Pharma Two B Ltd., a privately held biopharmaceutical company focused on developing treatments for
Pharma Two B Announces Positive Results in its Phase IIb Pivotal Clinical Study of P2B001 for the Treatment of Early Stage Parkinson’s Disease
Rehovoth, Israel, June 30, 2015 — Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously
Pharma Two B Announces Positive Results in its Phase IIb Pivotal Clinical Study of P2B001 for the Treatment of Early Stage Parkinson’s Disease
Rehovoth, Israel, June 30, 2015 — Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously
Pharma Two B taking ‘synergistic’ approach in pursuit of 505(b)(2) approval
http://bit.ly/gS5LF5